Compare Funko Inc (FNKO) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Funko Inc vs Moderna, Inc. — how do they compare? Funko Inc trades at $6.23 (market cap $332.33M), while Moderna, Inc. trades at $60.51 (market cap $24.18B). The key difference: Moderna, Inc. is far larger — about 72.8× Funko Inc's market cap, and Funko Inc is trading nearer its 52-week high, Moderna, Inc. nearer its low. Which is the better fit depends on your goals.
| FNKO | MRNA | |
|---|---|---|
Market Cap | $332.33M | $24.18B |
Sector | Consumer Staples | Health |
52-Week High | $6.35 | $81.80 |
52-Week Low | $2.65 | $22.36 |
Enterprise Value | $552.98M | $20.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FNKO trades at $5.92, down 4.36% today, but maintains a bullish technical outlook with strong moving average signals. The company reported improved Q2 2026 results with 7% revenue growth to $207.7M and raised EBITDA guidance. Despite negative net margins, recent earnings beats and a low P/S ratio of 0.35 suggest undervaluation. Analyst sentiment is mixed with 43% buy ratings but no sell recommendations.
The outlook remains cautiously optimistic as Funko's turnaround strategy shows traction, though profitability challenges and negative cash flow from operations pose risks. The stock offers potential upside if management can sustain recent operational improvements and return to consistent profitability.
Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.
The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Funko Inc
Funko Inc is a US-based pop culture consumer products company. It creates whimsical, fun, and different products which enable the customer to express their affinity for their favorite through movie, TV show, video game, musician or sports team. The company holds licenses and the rights to create tens of thousands of characters including Game of Thrones, Walking Dead, Disney, Marvel, Harry Potter, Fallout, and others. Its products include Pop, Dorbz, Mystery Vinyl, Plush, Action Figures, and Others. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites.
Read more on FNKO →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
